A new licensing deal by Specialised Therapeutics will see Nerlynx (neratinib) available in Australia, NZ and South-East Asia for women with early stage HER2+ breast breast cancer.
The deal with US firm Puma Biotechnology will see the drug available to eligible women following standard-of-care adjuvant chemotherapy and a year of trastuzumab-based therapy.
Nerlynx is the first FDA-approved treatment for extended adjuvant therapy in early stage HER2+ breast cancer, with Specialised Therapeutics ceo Carlo Montagner saying it was a valuable inclusion to the firm's oncology portfolio.
The above article was sent to subscribers in Pharmacy Daily's issue from 24 Nov 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 24 Nov 17
